IL6 and osteoporosis: Notably, GLU172, LYS66, and ARG168 have been reported as key residues targeted by MD2-TLR4-IN-1, a potential IL-6 inhibitor that mitigates inflammation-driven bone loss in osteoporosis patients [42].